1365-2125/asset/olbannerleft.gif?v=1&s=e86b92cac3efbbd2e255b9fa97ece9623eac0b54)
1365-2125/asset/olbannerright.gif?v=1&s=6a7c47d290382bf3bc40c62461bc36a371a081bf)
Population pharmacokinetics of carbamazepine in Singapore epileptic patients
Article first published online: 27 MAR 2003
DOI: 10.1046/j.0306-5251.2001.01396.x
1365-2125/asset/cover.gif?v=1&s=3e2bd7e8ead66ccf0afe5cc2432c3cd173fcfb7f "British Journal of Clinical Pharmacology")
Additional Information
How to Cite
Chan, E., Lee, H. S. and Hue, S. S. (2001), Population pharmacokinetics of carbamazepine in Singapore epileptic patients. British Journal of Clinical Pharmacology, 51: 567–576. doi: 10.1046/j.0306-5251.2001.01396.x
Publication History
- Issue published online: 27 MAR 2003
- Article first published online: 27 MAR 2003
- Received 13 January 2000,accepted 13 February 2001.
- Abstract
- Article
- References
- Cited By
Keywords:
- carbamazepine;
- children and adults;
- NONMEM;
- pharmacogenetics;
- population pharmacokinetics;
- Singapore epileptic patients
Aims To document the population pharmacokinetics of carbamazepine in patients with epilepsy living in Singapore, the majority of whom are of Chinese origin and others of minority races.
Methods Steady-state plasma carbamazepine concentration data were gathered during routine care from various hospitals in Singapore for patients with epilepsy. Age, body weight, gender, race, formulation and concurrent medication (for other illnesses) were the fixed effects (covariates) tested simultaneously for their influence on the population mean of carbamazepine clearance, using the nonlinear mixed-effects model, in the NONMEM program.
Results No age, gender, race, or formulation–related effect was found. Body weight (W), age (A) and concurrent medication with phenobarbitone (PB) emerged as the determinants of carbamazepine clearance (CL). The final regression model for carbamazepine clearance found best to describe the data was CL = 40.7 × A0.494 × W−1.17 × 1.44PB where CL is in l day−1 kg−1, A is in years, W is in kg and PB = 0 for a patient on carbamazepine only and PB = 1 for a patient on concomitant PB. The corresponding interindividual variability (CV%) in CL, described by using an exponential model, was 21.4%, and the residual error, described by using an exponential error model, was 18.2%. Predictive performance of this population covariate model was evaluated by Bayesian forecasting in a similar, but independent cohort of patients. There was no statistically significant bias between predicted and measured plasma carbamazepine concentrations. The population mean value of carbamazepine clearance obtained was similar to that previously reported for patients with a very different ethnic (Caucasians and Blacks) or geographical background (South Africa, Europe and USA).
Conclusions The derived covariate regression model reasonably predicted concentrations in the separate validation Singapore patient data set. The correlation between carbamazepine clearance and patient-specific characteristics may thus allow dosage adjustment to be made to achieve target steady-state plasma concentrations.